Over-expression or amplification of the human epidermal growth factor receptor 2 (HER2), which is present in 15–30% of breast cancers, is associated with a more aggressive clinical phenotype and a worse prognosis [1, 2]. Here, ERBB2 is linked to breast carcinoma.